Innovation hub and accelerator supported by Microsoft, nurturing deep-tech startups in biotech, nanotech, and digital sectors. Provides acceleration, access to University of Minho labs, and corporate partners; backed 120+ companies.
Scope: Regional (Northern Portugal).
Braga, Portugal
Accelerator
/portugal/accelerator/startup-braga
Azafaros is a clinical-stage biotech company developing oral therapies for rare genetic metabolic disorders, including lysosomal diseases. Its lead development strategy focuses on compounds designed to cross the blood-brain barrier and address severe neurological progression in underserved pediatric conditions.
Bioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens. By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight. Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance. The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.
Generative protein design platform helping scientists engineer new vaccines, therapeutics, and materials.
DeepDrive is the Munich startup that convinced major automakers to rethink the electric motor itself. Its core innovation is a patented dual-rotor motor architecture. In a traditional motor, a single rotor spins inside a fixed stator. DeepDrive's design spins both the internal and external rotor simultaneously, delivering higher torque density and substantially better efficiency. The practical outcome is compelling: EVs can achieve roughly 20% more range with 50% less motor weight, while reducing bill-of-materials costs. By 2026, DeepDrive has moved beyond impressive prototypes to industrialization. The company has reportedly secured series nominations with eight of the top ten global automakers for platform launches in 2028–2029. That level of OEM validation is rare at this stage and signals confidence in both the performance and manufacturability of the design. The company is now focused on building automated production lines in northern Munich to scale output for fleet testing and pre-series runs. A particularly strategic application is the in-wheel motor. Because the dual-rotor unit is compact and lightweight, it can fit inside the wheel hub, freeing up interior volume and enabling fully flat skateboard platforms. That creates new possibilities for autonomous shuttles and urban delivery vehicles where maximizing passenger or cargo space is paramount. It also allows for advanced vehicle dynamics such as torque vectoring without complex drivetrain components, improving both safety and handling. DeepDrive is a classic spin-out from the UnternehmerTUM ecosystem at TU Munich, with early validation support from the XPRENEURS incubator. Its investor base blends strategic automotive capital with deep-tech venture funding: Leitmotif led the Series B, BMW i Ventures provides rare early-stage OEM participation, Continental's corporate VC is a strategic partner for braking and chassis integration, and UVC Partners and Bayern Kapital anchor local support. In 2026, DeepDrive is one of Europe’s most promising hardware deep-tech bets: a motor breakthrough with clear OEM pull, manufacturability momentum, and the potential to reshape EV platform design.
Hemab is a clinical-stage biotech company developing prophylactic therapies for severe bleeding and thrombotic disorders. Founded by biotech operators with Novo Nordisk roots, the company engineers antibody-based treatments aimed at preventing episodes before they occur in underserved rare-disease populations.
Biotech skincare startup developing bio-identical melanin from stem-cell-based processes to improve UV protection and skin health. The company focuses on long-duration photoprotection and alternatives to conventional sunscreen formulations.
Checking login status...
Loading comments...